News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
72,565 Results
Type
Article (6183)
Company Profile (30)
Press Release (66352)
Multimedia
Podcasts (10)
Webinars (3)
Section
Business (16173)
Career Advice (380)
Deals (3143)
Drug Delivery (19)
Drug Development (8112)
Employer Resources (21)
FDA (1723)
Job Trends (2135)
News (28802)
Policy (2194)
Tag
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (206)
Accelerated approval (11)
Adcomms (1)
Allergies (32)
Alliances (4172)
ALS (54)
Alzheimer's disease (227)
Antibody-drug conjugate (ADC) (82)
Approvals (1909)
Artificial intelligence (135)
Autoimmune disease (37)
Automation (9)
Bankruptcy (30)
Best Places to Work (1695)
BIOSECURE Act (1)
Biosimilars (59)
Biotechnology (21)
Bladder cancer (62)
Brain cancer (19)
Breast cancer (200)
Cancer (1405)
Cardiovascular disease (116)
Career advice (335)
Career pathing (10)
CAR-T (70)
CDC (8)
Cell therapy (181)
Cervical cancer (11)
Clinical research (8074)
Collaboration (454)
Compensation (368)
Complete response letters (10)
COVID-19 (194)
CRISPR (18)
C-suite (186)
Cystic fibrosis (43)
Data (1937)
Decentralized trials (1)
Denatured (3)
Depression (31)
Diabetes (114)
Diagnostics (986)
Digital health (12)
Diversity (2)
Diversity, equity & inclusion (2)
Drug discovery (56)
Drug pricing (15)
Drug shortages (3)
Duchenne muscular dystrophy (110)
Earnings (8584)
Editorial (15)
Employer branding (2)
Employer resources (21)
Events (13312)
Executive appointments (233)
FDA (2710)
Fibrodysplasia Ossificans Progressiva (3)
Frontotemporal dementia (3)
Funding (265)
Gene editing (39)
Generative AI (15)
Gene therapy (130)
GLP-1 (127)
Government (302)
Guidances (151)
Healthcare (1882)
HIV (22)
Huntington's disease (11)
IgA nephropathy (19)
Immunology and inflammation (34)
Immuno-oncology (13)
Indications (31)
Infectious disease (248)
Inflammatory bowel disease (31)
Inflation Reduction Act (3)
Influenza (33)
Intellectual property (56)
Interviews (65)
IPO (1418)
IRA (6)
Job creations (639)
Job search strategy (286)
JPM (13)
Kidney cancer (8)
Labor market (41)
Layoffs (97)
Leadership (9)
Legal (403)
Liver cancer (15)
Longevity (2)
Lung cancer (182)
Lymphoma (152)
Machine learning (8)
Management (11)
Manufacturing (150)
MASH (36)
Medical device (1866)
Medtech (1878)
Mergers & acquisitions (2035)
Metabolic disorders (243)
Multiple sclerosis (40)
NASH (1)
Neurodegenerative disease (48)
Neuropsychiatric disorders (9)
Neuroscience (486)
Neurotech (1)
NextGen: Class of 2026 (872)
Non-profit (282)
Now hiring (25)
Obesity (83)
Opinion (43)
Ovarian cancer (44)
Pain (39)
Pancreatic cancer (87)
Parkinson's disease (55)
Partnered (25)
Patents (110)
Patient recruitment (103)
Peanut (9)
People (4672)
Pharmaceutical (11)
Pharmacy benefit managers (3)
Phase 1 (2660)
Phase 2 (3659)
Phase 3 (2889)
Pipeline (1603)
Policy (39)
Postmarket research (150)
Preclinical (993)
Press Release (3)
Prostate cancer (73)
Psychedelics (3)
Radiopharmaceuticals (70)
Rare diseases (231)
Real estate (525)
Recruiting (12)
Regulatory (2555)
Reports (28)
Research institute (218)
Resumes & cover letters (56)
Rett syndrome (17)
RNA editing (5)
RSV (15)
Schizophrenia (31)
Series A (34)
Series B (32)
Service/supplier (3)
Sickle cell disease (25)
Special edition (21)
Spinal muscular atrophy (13)
Sponsored (12)
Startups (470)
Stomach cancer (1)
Supply chain (20)
Tariffs (5)
The Weekly (7)
Vaccines (150)
Venture capital (14)
Weight loss (40)
Women's health (25)
Worklife (6)
Date
Last 7 days (172)
Last 30 days (578)
Last 365 days (8863)
2026 (772)
2025 (9104)
2024 (9219)
2023 (5117)
2022 (5230)
2021 (5188)
2020 (4785)
2019 (4184)
2018 (3127)
2017 (4306)
2016 (3358)
2015 (3195)
2014 (2080)
2013 (1408)
2012 (1550)
2011 (1595)
2010 (1390)
Location
Africa (193)
Alabama (8)
Alaska (1)
Arizona (30)
Asia (5024)
Australia (745)
California (3632)
Canada (813)
China (216)
Colorado (169)
Connecticut (197)
Delaware (140)
Europe (8695)
Florida (473)
Georgia (134)
Idaho (5)
Illinois (304)
India (28)
Indiana (161)
Iowa (8)
Japan (171)
Kansas (6)
Kentucky (5)
Louisiana (5)
Maine (2)
Maryland (313)
Massachusetts (2699)
Michigan (75)
Minnesota (75)
Mississippi (2)
Missouri (20)
Montana (8)
Nebraska (5)
Nevada (17)
New Hampshire (14)
New Jersey (975)
New Mexico (1)
New York (831)
North Carolina (264)
North Dakota (1)
Northern California (1708)
Ohio (60)
Oregon (6)
Pennsylvania (660)
Puerto Rico (1)
Rhode Island (9)
South America (230)
South Carolina (3)
Southern California (1583)
Tennessee (18)
Texas (478)
United States (11806)
Utah (82)
Virginia (30)
Washington D.C. (28)
Washington State (238)
West Virginia (2)
Wisconsin (40)
72,565 Results for "google x".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Model Medicines to Present 325 Billion Molecule Throughput Oncology Screen, at Google Cloud’s Cancer AI Symposium
At Google Cloud’s second annual Cancer AI Symposium, Model Medicines will unveil how its GALILEO™ platform, built on Google Cloud, powered a 325 billion molecule throughput oncology screen — the largest of its kind — opening the door to trillion‑scale discovery and culminating in the discovery of MDL‑4102, a potent and selective BRD4 inhibitor.
October 30, 2025
·
1 min read
Rare diseases
Harmony Freezes Cannabidiol Gel After Phase III Miss in Fragile X Syndrome
Harmony Biosciences has paused a mid-stage trial of ZYN002 in 22q11.2 deletion syndrome after the THC-free cannabinoid drug failed to significantly improve social avoidance in a late-stage study in fragile X Syndrome.
November 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
February 5, 2026
·
9 min read
Press Releases
BioMed X Launches XBridge Pilot to Facilitate Industry-Academic Research Collaborations
January 13, 2026
·
1 min read
Press Releases
Byonyks X1: Revolutionizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.
February 4, 2026
·
3 min read
Press Releases
Byonyks X1: Revolutinizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.
February 3, 2026
·
3 min read
Press Releases
10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling
January 13, 2026
·
7 min read
Press Releases
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease
January 13, 2026
·
6 min read
Press Releases
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results
January 12, 2026
·
8 min read
Press Releases
Signios Bio Launches Xenium 5K Spatial Transcriptomics Grant Program in Collaboration with 10x Genomics
January 27, 2026
·
2 min read
1 of 7,257
Next
